

Product Data Sheet

Product Name: OTUB2-IN-1

Cat. No.: GC71471

Chemical Properties

Cas. No.


Formula $C_{19}H_{18}N_2O_6S_2$ M.Wt 434.49

Solubility DMSO : 50 mg/mL (115.08 mM); Storage 4°C, protect from light
Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

OTUB2-IN-1, a specific inhibitor of OTUB2 (KD: ~12 μ M), reduces PD-L1 protein expression in tumor cells and inhibits tumor growth by promoting robust intra-tumor infiltration of cytotoxic T lymphocytes (CTL) .

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

OTUB2-IN-1 (0-40 μ M) reduces PD-L1 levels in tumor cells (NCI-H358, SK-MES-1, and NCI-H226) in a dose-dependent manner, but it is unable to affect OTUB2 stability^[1].

OTUB2-IN-1 (0-50 μ M; 1 h) does not interfere with protein interactions between OTUB2 and PD-L1^[1].

OTUB2-IN-1 (10 μ M; 0-4 d) can't inhibit the viability of B16-F10 tumor cells ^[1].

OTUB2-IN-1 (20 mg/kg; i.p.; daily for five days) suggests the potential to enhance immune recognition and immune response of tumor cells in mice implanted with B16-F10 cells^[1].

OTUB2-IN-1 (20 mg/kg; i.p.; daily for five days) reduces the expression of YAP and phosphorylated p65 in mice implanted with LL/2 cells; reduces phosphorylated Akt expression in mice implanted with B16-F10 cells and it reduces phosphorylated p65 expression in mice implanted with KLN205 cells^[1].

References:

[1]. Ren W et al. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1. Nat Commun. 2024 Jan 2;15(1):9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA